The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
The oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase selectivity and pharmacokinetics. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3743865?pdf=render |
| _version_ | 1828879317590867968 |
|---|---|
| author | Jasjeet Bhullar Karthika Natarajan Suneet Shukla Trevor J Mathias Mariola Sadowska Suresh V Ambudkar Maria R Baer |
| author_facet | Jasjeet Bhullar Karthika Natarajan Suneet Shukla Trevor J Mathias Mariola Sadowska Suresh V Ambudkar Maria R Baer |
| author_sort | Jasjeet Bhullar |
| collection | DOAJ |
| description | The oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase selectivity and pharmacokinetics. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Co-administration with chemotherapy is planned. We characterized interactions of quizartinib with the ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Its effects on uptake of fluorescent substrates and apoptosis were measured by flow cytometry, binding to ABCB1 and ABCG2 drug-binding sites by effects on [¹²⁵I]iodoarylazidoprazosin ([¹²⁵I]-IAAP) photolabeling and ATPase activity, and cell viability by the WST-1 colorimetric assay. Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5 µM and from 0.5 to 10 µM, respectively, and inhibited [¹²⁵I]-IAAP photolabeling of ABCG2 and ABCB1 with IC₅₀ values of 0.07 and 3.3 µM, respectively. Quizartinib at higher concentrations decreased ABCG2, but not ABCB1, ATPase activity. Co-incubation with quizartinib at 0.1 to 1 µM sensitized ABCG2-overexpressing K562/ABCG2 and 8226/MR20 cells to ABCG2 substrate chemotherapy drugs in a concentration-dependent manner in cell viability and apoptosis assays. Additionally, quizartinib increased cellular uptake of the ABCG2 substrate fluoroquinolone antibiotic ciprofloxacin, which also prolongs the QT interval, in a concentration-dependent manner, predicting altered ciprofloxacin pharmacokinetics and pharmacodynamics when co-administered with quizartinib. Thus quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. These interactions should be considered in the design of treatment regimens combining quizartinib and chemotherapy drugs and in choice of concomitant medications to be administered with quizartinib. |
| first_indexed | 2024-12-13T09:25:07Z |
| format | Article |
| id | doaj.art-ab5b8f0484cd41be89e70542266bb8b9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T09:25:07Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ab5b8f0484cd41be89e70542266bb8b92022-12-21T23:52:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e7126610.1371/journal.pone.0071266The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.Jasjeet BhullarKarthika NatarajanSuneet ShuklaTrevor J MathiasMariola SadowskaSuresh V AmbudkarMaria R BaerThe oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase selectivity and pharmacokinetics. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Co-administration with chemotherapy is planned. We characterized interactions of quizartinib with the ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Its effects on uptake of fluorescent substrates and apoptosis were measured by flow cytometry, binding to ABCB1 and ABCG2 drug-binding sites by effects on [¹²⁵I]iodoarylazidoprazosin ([¹²⁵I]-IAAP) photolabeling and ATPase activity, and cell viability by the WST-1 colorimetric assay. Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5 µM and from 0.5 to 10 µM, respectively, and inhibited [¹²⁵I]-IAAP photolabeling of ABCG2 and ABCB1 with IC₅₀ values of 0.07 and 3.3 µM, respectively. Quizartinib at higher concentrations decreased ABCG2, but not ABCB1, ATPase activity. Co-incubation with quizartinib at 0.1 to 1 µM sensitized ABCG2-overexpressing K562/ABCG2 and 8226/MR20 cells to ABCG2 substrate chemotherapy drugs in a concentration-dependent manner in cell viability and apoptosis assays. Additionally, quizartinib increased cellular uptake of the ABCG2 substrate fluoroquinolone antibiotic ciprofloxacin, which also prolongs the QT interval, in a concentration-dependent manner, predicting altered ciprofloxacin pharmacokinetics and pharmacodynamics when co-administered with quizartinib. Thus quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. These interactions should be considered in the design of treatment regimens combining quizartinib and chemotherapy drugs and in choice of concomitant medications to be administered with quizartinib.http://europepmc.org/articles/PMC3743865?pdf=render |
| spellingShingle | Jasjeet Bhullar Karthika Natarajan Suneet Shukla Trevor J Mathias Mariola Sadowska Suresh V Ambudkar Maria R Baer The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS ONE |
| title | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. |
| title_full | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. |
| title_fullStr | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. |
| title_full_unstemmed | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. |
| title_short | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. |
| title_sort | flt3 inhibitor quizartinib inhibits abcg2 at pharmacologically relevant concentrations with implications for both chemosensitization and adverse drug interactions |
| url | http://europepmc.org/articles/PMC3743865?pdf=render |
| work_keys_str_mv | AT jasjeetbhullar theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT karthikanatarajan theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT suneetshukla theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT trevorjmathias theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT mariolasadowska theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT sureshvambudkar theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT mariarbaer theflt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT jasjeetbhullar flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT karthikanatarajan flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT suneetshukla flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT trevorjmathias flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT mariolasadowska flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT sureshvambudkar flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions AT mariarbaer flt3inhibitorquizartinibinhibitsabcg2atpharmacologicallyrelevantconcentrationswithimplicationsforbothchemosensitizationandadversedruginteractions |